Literature DB >> 10025668

Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors.

J Faust1, D L Lacey, P Hunt, T L Burgess, S Scully, G Van, A Eli, Y Qian, V Shalhoub.   

Abstract

Recent studies show that human osteoclasts develop in vitro from hematopoietic cells; however, special cultures conditions and/or cytokine mobilized peripheral blood are apparently required. Here, we report that cells expressing osteoclast markers differentiate from precursors present in nonmobilized peripheral blood mononuclear cells (PBMC), without the addition of stromal cells, growth factors, cytokines or steroids; and characterize their phenotype. Three days after establishing high-density PBMC cultures (1.5 x 10(6) cells/cm2), in serum-containing medium, small adherent colonies of tartrate resistant acid phosphatase positive (TRAP+) cells emerge, amidst massive monocyte cell death. These adherent cells have an eccentrically placed, round nucleus, and express low levels of TRAP and sodium fluoride-resistant- alpha-naphthyl-acetate-esterase (NaF-R-NSE). Over the next week, this cell population accumulates phenotypic markers of osteoclasts (vitronectin receptor [VR], calcitonin receptor, TRAP, cathepsin K protein, and mRNA) with increased nuclearity, covering the entire surface by 15 days. When cultured on bone, VR+, TRAP+ cells of low multinuclearity appear and cover up to 50% of the surface. Resorption lacunae can be observed by day 22. Although these pits are not nearly as numerous as the cells of preosteoclast phenotype, they do represent the activity of a subset of osteoclast-like cells that has achieved osteoclastic maturity under these culture conditions. Transcripts for osteoprotegerin ligand (OPGL), an osteoclast differentiation factor (also known as RANKL and TRANCE) are expressed, likely by adherent cells. Thus, an adherent population of cells, with preosteoclast/osteoclast phenotypic properties, arises selectively under simple culture conditions from normal PBMC. Further characterization of these cells should identify factors involved in the growth, terminal differentiation and activation of osteoclasts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025668     DOI: 10.1002/(sici)1097-4644(19990101)72:1<67::aid-jcb8>3.0.co;2-a

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  23 in total

1.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Authors:  D L Lacey; H L Tan; J Lu; S Kaufman; G Van; W Qiu; A Rattan; S Scully; F Fletcher; T Juan; M Kelley; T L Burgess; W J Boyle; A J Polverino
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Spontaneous and induced osteoclastogenic behaviour of human peripheral blood mononuclear cells and their CD14(+) and CD14(-) cell fractions.

Authors:  J Costa-Rodrigues; A Fernandes; M H Fernandes
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

Review 3.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

Authors:  Linda Demer; Yin Tintut
Journal:  Circ Res       Date:  2011-06-10       Impact factor: 17.367

4.  Expression of typical osteoclast markers by PBMCs after PEG-induced fusion as a model for studying osteoclast differentiation.

Authors:  Luz M Castillo; Carlos A Guerrero; Orlando Acosta
Journal:  J Mol Histol       Date:  2017-03-25       Impact factor: 2.611

5.  TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis.

Authors:  A R Pettit; H Ji; D von Stechow; R Müller; S R Goldring; Y Choi; C Benoist; E M Gravallese
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  Influence of receptor activator of nuclear factor (NF)-kappaB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) and fetal calf serum on human osteoclast formation and activity.

Authors:  Ludwika Kreja; Astrid Liedert; Carla Schmidt; Lutz Claes; Anita Ignatius
Journal:  J Mol Histol       Date:  2007-06-19       Impact factor: 2.611

Review 7.  Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.

Authors:  A Sabokbar; D J Mahoney; F Hemingway; N A Athanasou
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

8.  In vitro method for the screening and monitoring of estrogen-deficiency osteoporosis by targeting peripheral circulating monocytes.

Authors:  Francesca Salamanna; Melania Maglio; Gianluca Giavaresi; Stefania Pagani; Roberto Giardino; Milena Fini
Journal:  Age (Dordr)       Date:  2015-08-07

9.  Alendronate reduces osteoclast precursors in osteoporosis.

Authors:  P D'Amelio; A Grimaldi; M A Cristofaro; M Ravazzoli; P A Molinatti; G P Pescarmona; G C Isaia
Journal:  Osteoporos Int       Date:  2009-12-01       Impact factor: 4.507

10.  Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts.

Authors:  Darrell Pilling; Ted Fan; Donna Huang; Bhavika Kaul; Richard H Gomer
Journal:  PLoS One       Date:  2009-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.